Procept BioRobotics today released early results from a study of its AquaBeam waterjet ablation therapy system designed for the endoscopic resection of prostate tissue exploring its use in treating benign prostatic hyperplasia, touting that it already met its primary safety and efficacy endpoints. Results were presented at the American Urological Association’s annual meeting in San Francisco […]
Procept BioRobotics raises $118m for Aquablation prostate treatment
Procept BioRobotics said today that it raised $118 million in an equity round it plans to use on the commercialization of its Aquablation treatment for benign prostate hyperplasia. Redwood Shores, Calif.-based Procept said new backer Viking Global Investors led the round, joined by Perceptive Advisors and existing investors including CPMG. The Aquablation treatment combines Procept’s Aquabeam – […]
Procept BioRobotics wins de novo nod from FDA for Aquabeam prostate treatment
Procept BioRobotics said today that it won de novo clearance from the FDA for its Aquabeam device for treating benign prostate hyperplasia, saying it plans to have the device on the U.S. market early next year. Redwood Shores, Calif.-based Procept said the federal safety watchdog used the 181-patient Water study to inform its decision. The trial, comparing Aquablation […]
Procept BioRobotics launches AquaBeam trial in France
Procept BioRobotics said today that it launched a clinical trial aimed at winning reimbursement approval in France for its AquaBeam prostate treatment. Redwood Shores, Calif.-based Procept said the 30-patient Francais Water study is designed to evaluate the safety and effectiveness of prostate ablation via waterjet in treating benign prostate hyperplasia in men aged 45 to 80. […]
Procept BioRobotics treats first patients in Water II test of surgical robot
Procept BioRobotics announced today that the first patients were treated in its Water II Study, a clinical trial testing the safety and efficacy of Aquablation delivery by its surgical robotic AquaBeam System to treat benign prostatic hyperplasia. The trials test the use of the system in prostates 80 to150 mL and will enroll 100 patients […]
7 medtech stories we missed this week: May 26, 2017
From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. […]
Procept BioRobotics launches AquaBeam trial
Procept BioRobotics said today it treated the 1st patients in a clinical trial of its AquaBeam water ablation therapy system designed to treat prostate disease. The Water study is a phase III clinical study evaluating the safety and effectiveness of the system compared to transurethral resection of the prostate, the current standard of care for […]
Procept BioRobotics closes $42m round for AquaBeam prostate device
Procept BioRobotics said today that it closed on a $42 million round for its AquaBeam “waterjet ablation” device for treating prostate cancer. Redwood Shores, Calif.-based Procept said the round was led by Novo Nordisk’s (NYSE:NVO) investment arm, Novo A/S, with new backer CPMG and existing investors also contributing. The AquaBeam device uses a high-pressure water jet […]
MassDevice Network
@MassDevice
LinkedIn
Google+